A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-110
SponsorNovartis Pharmaceuticals
About this trial
This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.
Eligibility criteria
Qualifiers
Patients with ≥1 International Classification of Diseases Clinical Modification, 10th revision (ICD-10-CM) diagnosis code for GEP-NET between 01 January 2018 and 31 December 2025. The date of the first such claim will be defined as the diagnosis date.
Initiation of first-line (1L) systemic therapy (i.e., somatostatin analogs [SSAs], targeted therapy, peptide receptor radionuclide therapy [PRRT], chemotherapy) indicated for GEP-NET on or after the date of diagnosis. The date of treatment initiation will be defined as the index date.
Patients ≥18 years of age on the index date
≥1 medical and pharmacy claim >12 months prior to the index date; AND
Disqualifiers
Patients with evidence of GEP-NET prior to the diagnosis date within the study period
Patients with evidence of GEP-NET treatment prior to the index date within the study period
Patients with missing or invalid age or sex
Patients with other primary malignancies during the 12-month pre-index period
Trial design
Treatments tested in this trial
- Not listed
Trial groups
4,023 Participants
are grouped into 7 trial groups7
Trial groupsSee each trial group below.
Locations
Sponsors and collaborators
Source ClinicalTrials.gov